Acyclovir is NOT an appropriate treatment for CMV pneumonia
Acyclovir should not be used for CMV pneumonia—it lacks sufficient antiviral activity against CMV and has demonstrated clinical ineffectiveness in this setting. The FDA-approved indications for acyclovir specifically exclude CMV infections, covering only herpes simplex virus (HSV) and varicella-zoster virus (VZV) 1.
Why Acyclovir Fails Against CMV
The fundamental problem is mechanistic: acyclovir requires viral thymidine kinase (TK) for activation, which CMV does not produce 1. While CMV may show some in vitro sensitivity at very high concentrations (10-25 mg/L), this does not translate to clinical efficacy 2.
Clinical Evidence of Failure
Historical studies definitively demonstrate acyclovir's ineffectiveness for CMV pneumonia:
In bone marrow transplant recipients with biopsy-proven CMV pneumonia, high-dose acyclovir (400-1200 mg/m²) achieved peak plasma levels of 47-316 μM but resulted in only 1 survivor out of 8 patients—essentially no improvement over the baseline 90% mortality rate 3.
A larger trial of 21 allogeneic marrow transplant recipients treated with high-dose acyclovir (with or without interferon) showed "no consistent effect on survival, viral titers, or viral shedding" 2. While 4 patients survived, this was attributed to possible strain variability rather than drug efficacy.
What Should Be Used Instead
For CMV pneumonia, use ganciclovir or valganciclovir as first-line therapy 4, 5. These agents are specifically designed for CMV and have demonstrated clinical efficacy:
- Ganciclovir/valganciclovir remain the drugs of choice for CMV disease management 4, 5
- For resistant or refractory cases, foscarnet or maribavir are recommended alternatives 4
- Maribavir has shown higher response rates and lower organ toxicity compared to investigator-assigned alternatives in resistant CMV 4
Important Caveat
The evidence showing acyclovir's ineffectiveness comes primarily from severely immunocompromised bone marrow transplant patients 2, 3. The authors suggested it "may be more effective in patients with lesser degrees of immunosuppression" 2, but this remains unproven and should not guide clinical practice for established CMV pneumonia.
Clinical Algorithm
- Confirm CMV pneumonia diagnosis (tissue biopsy, BAL with quantitative PCR)
- Initiate ganciclovir IV (5 mg/kg every 12 hours) or valganciclovir PO (900 mg twice daily if able to take oral medications)
- If refractory or resistant: Switch to foscarnet or maribavir based on resistance testing 4
- Never use acyclovir as primary therapy for CMV pneumonia
The only potential role for high-dose acyclovir in CMV management is prophylaxis in low-risk solid organ transplant recipients (D-/R+ without lymphocyte depletion) 6, but this is distinctly different from treating active CMV pneumonia.